Several European health authorities have completed the assessment of a new, low-volume presentation size for the existing indications of Berinert, a human plasma-derived, pasteurized, and nanofiltered C1-esterase inhibitor (C1-INH) concentrate from CSL Behring. It is indicated for the treatment and pre-procedure prevention of acute episodes of HAE type I and II.
“This new vial size containing 1500 International Units of C1-esterase inhibitor is reconstituted with only 3mL of solvent and thus provides a new and convenient choice for patients of the appropriate body-weight”, said Prof. Markus Magerl M.D., Department of Dermatology and Allergy, Charité–Universitätsmedizin, Berlin, Germany. “As it can be prepared and administered faster than the same dose using the existing vial size of 500IU, we think it will be appreciated by many patients.”
The new Berinert 1500IU vial size will be available in several European countries following the respective national implementation phase. The existing vials size and formulation (Berinert 500IU) will also remain available.
“We believe that this new presentation of Berinert provides patients an additional choice that features all the known advantages of the existing product with additional practical and convenience attributes”, commented Debbie Drane, Vice President Global Commercial Development, CSL Behring. “Many patients will need fewer vials for the same dose, which not only saves time to treatment but also means less storage room, less ancillaries needed and less waste.”
(Source: CSL Behring)